

Vol 48 No 5
May 1999

Metabolism

Clinical and Experimental

HEALTH SCIENCES LIBRARY
University of Wisconsin

MAY 17 1999

1305 Linden Drive
Madison, WI 53706

Diabetes
Metabolism
Nutrition
Lipid Abnormalities
Endocrinology
Genetics
Gout

W. B. Saunders Company
A Division of Harcourt Brace & Company

Metabolism

Clinical and Experimental

Metabolism: Clinical and Experimental (ISSN 0026-0495) is published monthly by W.B. Saunders Company. Corporate and Editorial Offices: The Curtis Center, Independence Square West, Philadelphia, PA 19106-3399. Accounting and Circulation Offices: 6277 Sea Harbor Dr, Orlando, FL 32887-4800. Periodicals postage paid at Orlando, FL 32862, and at additional mailing offices.

POSTMASTER: Send change of address to *Metabolism*, c/o W.B. Saunders Company, Periodicals Department, 6277 Sea Harbor Dr, Orlando, FL 32887-4800.

Editorial correspondence should be addressed to James B. Field, MD, Eight Windmill Point Lane, Hampton, VA 23664-2129.

Correspondence regarding subscriptions or change of address should be addressed to W.B. Saunders Company, Periodicals Department, 6277 Sea Harbor Dr, Orlando, FL 32887-4800.

Change of address notices, including both the old and new addresses of the subscriber, should be sent at least one month in advance.

Customer Service: (800) 654-2452; outside the United States and Canada, (407) 345-4000.

Yearly subscription rates: United States and possessions: individual, \$233.00; institution, \$321.00; single issues, \$37.00. All other countries: individual, \$376.00; institution, \$440.00; single issues, \$37.00. For all areas outside the United States and possessions, there is no additional charge for surface delivery. For air mail delivery, add \$48.00. Student/Resident rate: United States and possessions, \$174.00; all other countries, \$376.00. To receive student/resident rate, orders must be accompanied by name of affiliated institution, date of term, and the *signature* of program/residency coordinator on institution letterhead. Orders will be billed at individual rate until proof of status is received. Journal orders are payable in advance. Current prices are in effect for back volumes and back issues. Back issues sold in conjunction with a subscription are on a prorated basis. Single issues, both current and back, exist in limited quantities and are offered for sale subject to availability. Prices are subject to change without notice. **Checks** should be made payable to W.B. Saunders Company, and sent to *Metabolism*, W.B. Saunders Company, Periodicals Department, PO Box 628239, Orlando, FL 32862-8239.

Copyright © 1999 by W.B. Saunders Company. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means now or hereafter known, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the publisher. Printed in the United States of America.

Correspondence regarding permission to reprint all or part of any article published in this journal should be addressed to Journal Permissions Department, W.B. Saunders Company, Orlando, FL 32887. Telephone 1-407-345-2500.

Other correspondence (copy editing, production) should be addressed to W.B. Saunders Company, The Curtis Center, Independence Square West, Philadelphia, PA 19106-3399.

The appearance of the code at the bottom of the first page of an article in this journal indicates the copyright owner's consent that copies of the article may be made for personal or internal use, or for the personal or internal use of specific clients, for those registered with the Copyright Clearance Center, Inc. (222 Rosewood Drive, Danvers, MA 01923; (508) 750-8400; www.copyright.com). This consent is given on the condition that the copier pay the stated per-copy fee for that article through the Copyright Clearance Center, Inc. for copying beyond that permitted by Sections 107 or 108 of the US Copyright Law. This consent does not extend to other kinds of copying, such as copying for general distribution, for advertising or promotional purposes, for creating new collective works, or for resale. Absence of the code indicates that the material may not be processed through the Copyright Clearance Center, Inc.

Advertising representative: M.J. Mrvica Associates, Inc, 155 South White Horse Pike, Berlin, NJ 08009. Telephone: 609-768-9360. Fax: 609-753-0064.

The ideas and opinions expressed in *Metabolism* do not necessarily reflect those of the Editor or the Publisher. Publication of an advertisement or other product mention in *Metabolism* should not be construed as an endorsement of the product or the manufacturer's claims. Readers are encouraged to contact the manufacturer with any questions about the features or limitations of the products mentioned. The Publisher does not assume any responsibility for any injury and/or damage to persons or property arising out of or related to any use of the material contained in this periodical. The reader is advised to check the appropriate medical literature and the product information currently provided by the manufacturer of each drug to be administered to verify the dosage, the method and duration of administration, or contraindications. It is the responsibility of the treating physician or other health care professional, relying on independent experience and knowledge of the patient, to determine drug dosages and the best treatment for the patient.

W.B. Saunders Company



Philadelphia, PA

A Division of Harcourt Brace & Company

Supplementation With Vitamin B₁₂ Decreases Homocysteine and Methylmalonic Acid But Also Serum Folate in Patients With End-Stage Renal Disease

Jutta Dierkes, Ute Domröse, Andreas Ambrosch, Joern Schneede, Anne Berit Guttormsen, Klaus Hinrich Neumann, and Claus Luley

Hyperhomocysteinemia is frequently found in patients with end-stage renal disease (ESRD). Plasma total homocysteine (tHcy) concentrations may be reduced by supplementation with folic acid or combinations of folic acid, vitamin B₁₂, and vitamin B₆. Supplementation studies with vitamin B₁₂ alone in patients with ESRD have not yet been published. In this study, we investigated the effects of intravenous injection of cyanocobalamin (1 mg/wk for 4 weeks) in ESRD patients (N = 14) with low serum cobalamin concentrations (<180 pmol/L). All patients had elevated levels of plasma tHcy, methylmalonic acid (MMA), and cystathionine before supplementation. After supplementation, plasma tHcy and MMA decreased 35% and 48%, respectively; however, cystathionine levels were unchanged. The extent of the plasma tHcy reduction tended to be influenced by the C677T polymorphism of methylenetetrahydrofolate reductase (MTHFR). Serum cobalamin increased significantly upon supplementation, whereas serum folate levels were substantially reduced by 47%. In contrast, red blood cell (RBC) folate was unchanged. This study shows that vitamin B₁₂ supplementation effectively decreases both MMA and plasma tHcy in ESRD patients with low B₁₂ levels. Furthermore, it illustrates the close interrelation between vitamin B₁₂ and folate metabolism.
Copyright © 1999 by W.B. Saunders Company

TOTAL HOMOCYSTEINE (tHcy) is a metabolite of the essential amino acid methionine. Two known major pathways for the transformation of tHcy are remethylation to methionine or transsulfuration to cysteine. The remethylation requires methylcobalamin (one of the coenzyme forms of vitamin B₁₂) as a coenzyme and methyltetrahydrofolate (one of the metabolic active forms of folic acid) as a substrate, whereas the transsulfuration is dependent on pyridoxal-5-phosphate (the coenzyme form of vitamin B₆).

An elevated plasma concentration of tHcy is an independent risk factor for cardiovascular disease in patients with normal renal function. This association has been shown in both retrospective and prospective case-control studies.¹⁻³ Most studies demonstrated that the cardiovascular risk is increased already at the upper quartile of the reference range (12 to 16 μmol/L). Patients with end-stage renal disease (ESRD) have mildly to moderately elevated plasma tHcy concentrations, typically in the range of 20 to 80 μmol/L.^{4,5}

Mild to moderate hyperhomocysteinemia in subjects with normal renal function can be normalized in most cases by supplementation with either folic acid alone or combinations of folic acid with vitamin B₁₂ and/or vitamin B₆.⁶⁻⁸ However, there is only limited knowledge about the tHcy-lowering effect of vitamin B₁₂ alone. Ubbink et al⁷ studied healthy middle-aged men who received oral vitamin B₁₂ supplementation (400 μg daily for 6 weeks), and a 14% reduction of the elevated plasma tHcy was observed. Patients with non-insulin-dependent diabetes mellitus were investigated by Araki et al.⁹ The patients received 1 mg vitamin B₁₂ intramuscularly daily for 3 weeks, and a 30% decrease of plasma tHcy was reported.

Elevated plasma tHcy concentrations are typically found in folate and/or cobalamin deficiency¹⁰⁻¹² but also in vitamin B₆ deficiency.¹³ Furthermore, the effects of these vitamin deficiencies may be modulated by the C677T genotype of methylenetetrahydrofolate reductase (MTHFR). A TT genotype is associated with decreased enzyme activity and increased tHcy in humans with low or low-normal serum folate concentrations.¹⁴ This has been observed both in humans with normal renal function and in patients with ESRD.¹⁵

Patients with ESRD have an increased risk to develop

vitamin deficiencies. In particular, vitamin B₁₂ metabolism may be affected by the disease itself,¹⁶ and low serum cobalamin concentrations are frequently observed in these patients. However, studies attempting to decrease tHcy using vitamin B₁₂ supplementation alone have not been performed in ESRD patients. Therefore, we investigated the effect of high-dose vitamin B₁₂ supplementation in patients with ESRD and low baseline serum cobalamin concentrations in relation to the MTHFR genotype.

SUBJECTS AND METHODS

Patients with ESRD from the Department of Nephrology at University Hospital Magdeburg who were clinically stable at the time of the study were eligible to participate. All underwent hemodialysis three times per week. Of 85 patients with ESRD, 14 had low serum cobalamin concentrations (<180 pmol/L) and were included in the study after provision of written informed consent. Characteristics of the patients are listed in Table 1. High-dose vitamin B₁₂ supplements (cyanocobalamin) were administered intravenously (1,000 μg once per week) for 4 weeks, each after dialysis. Blood samples were taken before dialysis at baseline and before dialysis after 4 weeks for measurement of plasma tHcy, serum and red blood cell (RBC) folate, and serum cobalamin, methylmalonic acid (MMA), and cystathionine. Serum and EDTA test tubes were cooled immediately, and the plasma was separated from the blood cells within 30 minutes and frozen at -20°C until analysis. Lysates of EDTA blood in ascorbic acid solution lysis reagent (Abbott Lab) were prepared for analysis of RBC folate according to the manufacturer's instructions and frozen at -20°C until analysis.

Plasma tHcy was determined in EDTA plasma with a high-performance liquid chromatographic method with fluorescence detection after derivatization with ammonium 7-fluorobenzo-2-oxa-1,3-diazole-4-sulfonate.¹⁷ The method has a between-day coefficient of variation of 5%; the reference range for plasma tHcy is 5 to 15 μmol/L.

MMA and cystathionine levels were measured in EDTA plasma using

From the Institute of Clinical Chemistry and Nephrology Clinic, University Hospital Magdeburg, Magdeburg, Germany; and Department of Pharmacology, University of Bergen, Bergen, Norway.

Submitted July 30, 1998; accepted October 23, 1998.

Address reprint requests to Jutta Dierkes, PhD, Institute of Clinical Chemistry, Leipziger Str. 44, D-39120 Magdeburg, Germany.

*Copyright © 1999 by W.B. Saunders Company
0026-0495/99/4805-0016\$10.00/0*

Table 1. Characteristics of the Hemodialysis Patients (N = 14)

Characteristic	Median	Range
Age (yr)	63.0	42-79
BMI (kg/m ²)	25.2	20.2-33.6
Duration of dialysis (mo)	33	5-78
Creatinine (μmol/L)	800	499-1,329
Male/female ratio	7/7	
C677T MTHFR genotype	CC = 5; CT = 7; TT = 2	

Abbreviations: BMI, body mass index; CC, wild-type; CT, heterozygous; TT, mutant.

a newly developed gas chromatographic method combined with mass spectrometry as described by Guttormsen et al.¹⁸ The method has a between-day coefficient of variation of 3% to 15% for both metabolites. The reference range for MMA is 0.05 to 0.26 μmol/L, but a reference range has not been established for cystathionine. However, the reference range for cystathionine in serum reported in the literature, based on a different method, is 0.065 to 0.301 μmol/L.¹⁹

Serum cobalamin and folate were analyzed using commercial test kits (Abbott IMx; Abbott Laboratories, Wiesbaden, Germany). The test kit measures total cobalamin in serum. Folate was analyzed both in serum and in RBCs. The reference range was more than 135 pmol/L for serum cobalamin, more than 6.4 nmol/L for serum folate, and more than 425 nmol/L for RBC folate.

For analysis of the C677T genotype of MTHFR, DNA was extracted from EDTA blood and the C677T genotype was assessed using polymerase chain reaction with subsequent enzymatic restriction analysis (*HinfI*) as described by Kluijtmans et al.²⁰

Statistical analysis was performed using the Statistical Package for the Social Sciences Version 6.13 (SPSS, Chicago, IL). Nonparametric tests were used for comparison of baseline and postsupplementation measurements. Spearman rank correlation coefficients are presented. A *P* level less than .05 was regarded as significant.

RESULTS

At baseline, none of the 14 patients were folate-deficient with RBC folate as the sole criterion to define folate deficiency; however, four patients had serum folate less than 6.4 nmol/L (cutoff point for folate deficiency). Serum cobalamin correlated weakly with RBC folate ($r = .43$, nonsignificant [NS]) but not serum folate ($r = .17$, NS). RBC folate was significantly correlated with serum folate ($r = .58$, $P = .03$). Plasma tHcy was elevated in all patients. It was correlated significantly with serum folate ($r = -.75$, $P = .001$) but only weakly with RBC folate ($r = -.49$, $P = .08$) and not with serum cobalamin ($r = .08$). MMA concentrations were not correlated with plasma tHcy ($r = .21$), serum folate ($r = -.07$), or RBC folate ($r = -.12$), but correlated weakly with serum cobalamin ($r = -.36$, $P = .2$).

Table 2. Effect of Vitamin Supplementation (N = 14)

Parameter	Baseline (n = 14)		After Supplementation (n = 14)		<i>P</i>
	Median	Range	Median	Range	
tHcy (μmol/L)	40.8	26.7-84.3	29.4	17.3-50.1	.01
MMA (μmol/L)	1.12	0.37-2.87	0.54	0.21-0.84	.001
Cystathionine (μmol/L)	1.40	0.50-5.10	1.68	0.61-2.46	NS
Vitamin B ₁₂ (pmol/L)	146	109-179	1,166	443-2,900	.001
RBC folate (nmol/L)	875	431-1,428	1,013	591-1,543	NS
Serum folate (nmol/L)	9.4	5.0-19.6	4.5	2.4-8.8	.001
Mean corpuscular volume (fL)	93.8	83.3-104.0	95.1	82.6-106.0	NS

Table 3. tHcy and Effect of Vitamin B₁₂ Supplementation in Relation to C677T Genotype of MTHFR

Parameter	No T Allele, CC (n = 5)		T Allele, CT or TT (n = 9)		<i>P</i>
	Median	Range	Median	Range	
tHcy (μmol/L)					
Baseline	34.6	26.7-84.3	45.7	31.2-71.2	NS
Postsupplementation	21.4	17.3-48.1	33.5	22.8-55.7	.04
tHcy ratio (%)*	62.7	54.3-65.2	72.8	45.2-110.1	.09
Serum folate ratio (%)*	58	43.7-63.1	50.5	28.5-96.7	NS

*Calculated as value after supplementation/value at baseline × 100.

The effects of B₁₂ supplementation on the plasma concentration of the investigated vitamins and metabolites are listed in Table 2. Plasma tHcy was significantly reduced after supplementation (-35%). The extent of this reduction was not correlated with baseline plasma tHcy ($r = -.25$), serum or RBC folate, or serum cobalamin ($r = .06$). Patients without a T allele in the MTHFR genotype had significantly lower plasma tHcy concentrations after supplementation ($P < .05$; Table 3 and Fig 1). MMA decreased, on average, by 48% after supplementation. The decrease was weakly related to the baseline serum cobalamin concentration ($r = -.49$, $P = .07$) but was independent of the MTHFR status. The reduction in plasma tHcy was strongly related to the reduction in MMA ($r = .64$, $P = .001$), and the correlation was influenced by the presence of a T allele in the MTHFR gene (Fig 2).

After supplementation, the median serum cobalamin increased significantly, whereas the mean corpuscular volume was unaltered. Also, the RBC folate concentration did not change significantly, whereas serum folate decreased 47% (Table 2). Of 14 patients, 13 had serum folate levels less than 6.4 nmol/L after supplementation. This decrease was positively related to the baseline folate level ($r = .49$, $P = .06$) and independent of the MTHFR genotype.

DISCUSSION

Thus far, recommendations for the treatment of hyperhomocysteinemia in ESRD patients focus on supplementation with folic acid either alone or in conjunction with other vitamins.²¹ In our study, we describe for the first time the efficacy of intravenous supplementation with vitamin B₁₂ alone in ESRD patients with low serum levels of cobalamin. High-dose vitamin B₁₂ substantially reduced the elevated plasma levels of both tHcy and MMA in this subgroup of ESRD patients.

The elevated levels of plasma tHcy and MMA and the concurrent reduction of these metabolites upon vitamin B₁₂




Fig 1. Effect of vitamin B₁₂ supplementation on tHcy in relation to the C677T MTHFR genotype. Open symbols are the baseline tHcy concentration, and solid symbols are the tHcy concentration after supplementation. Blood samples were taken before dialysis.

supplementation are regarded as indicative of true vitamin B₁₂ deficiency.^{22,23} However, the diagnostic usefulness of elevated MMA levels in patients with renal disease has been questioned.²⁴ We were able to show a substantial reduction of MMA after vitamin B₁₂ supplementation. Yet despite an average 35% reduction of tHcy and 48% reduction of MMA, a complete normalization of both metabolites was not achieved in any of the patients before dialysis. This tHcy reduction seemed to be influenced by the MTHFR genotype. Although the number of




Fig 2. Relative reduction of MMA and tHcy in relation to the C677T MTHFR genotype in dialysis patients after vitamin B₁₂ supplementation. (---) Regression line for patients with the CC genotype (slope not significantly different from zero); (—) regression line for patients with the CT (n = 7) and TT (n = 2) genotype.

patients is too small to make firm conclusions, it is worth noting that of nine patients with a T allele, four showed a reduction of homocysteine of less than 20% after vitamin B₁₂ supplementation (Fig 2).

We also found a pronounced decrease of serum folate but not RBC folate after supplementation with vitamin B₁₂. This was unexpected, as both folate parameters were within the normal range in all patients before B₁₂ supplementation. The reduction was strongly related to the baseline serum folate: the higher the




Fig 3. Schematic representation of potential changes in the extracellular concentration of tHcy and 5-methyltetrahydrofolate (CH₃-THF) in cobalamin deficiency and in response to supplementation with vitamin B₁₂. Shown are physiological (small print), subphysiological (small boldface), and supraphysiological (large boldface) concentrations. SAH, S-adenosylhomocysteine; SAM, S-adenosylmethionine; Met, methionine; THF, tetrahydrofolate; CH₃-THF, 5-methyltetrahydrofolate; Cbl, cobalamin; CH₃-Cbl, methylcobalamin.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.